Need professional-grade analysis? Visit stockanalysis.com
$8.30B
N/A
69
N/A
Abivax SA (ABVX) trades on Euronext Paris in EUR. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at EUR104.70, up 1.45% from the previous close.
Over the past year, ABVX has traded between a low of EUR5.06 and a high of EUR122.40. The stock has gained 1849.7% over this period. It is currently 14.5% below its 52-week high.
Abivax SA has a market capitalization of $8.30B.
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Side-by-side comparison against top Healthcare peers.